Cryo-Cell International, Inc.
$3.56
▲
0.83%
2026-04-21 05:56:00
www.cryo-cell.com
ASE: CCEL
Explore Cryo-Cell International, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$27.71 M
Current Price
$3.56
52W High / Low
$6.35 / $2.72
Stock P/E
—
Book Value
$-2.31
Dividend Yield
11.63%
ROCE
11.54%
ROE
15.27%
Face Value
—
EPS
$-0.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Care Facilities
Employees
72
Beta
0.63
Debt / Equity
-0.62
Current Ratio
0.59
Quick Ratio
0.57
Forward P/E
43.38
Price / Sales
0.89
Enterprise Value
$36.21 M
EV / EBITDA
24.68
EV / Revenue
1.15
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Meaningful dividend yield is available.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | DaVita Inc. | $149.93 | 15.78 | $10.02 B | — | 14.02% | 64.85% | $159.42 / $101 | $-9.5 |
| 2. | Astrana Health, Inc. | $31.45 | 69.19 | $1.56 B | 0.51% | 4.9% | 4.49% | $34.8 / $18.08 | $15.94 |
| 3. | Nutex Health Inc. | $109.28 | 11.86 | $761.5 M | 9.75% | 36.24% | 58.94% | $193.07 / $77.21 | $46.49 |
| 4. | Acadia Healthcare Company, Inc. | $27.84 | — | $2.56 B | — | 7.76% | -40.96% | $28.48 / $11.43 | $21.55 |
| 5. | agilon health, inc. | $28.3 | — | $499.01 M | — | -219.27% | -1.36% | $141 / $7.48 | $7.64 |
| 6. | DocGo Inc. | $0.68 | — | $64.06 M | — | -59.59% | -89.05% | $2.45 / $0.49 | $1.46 |
| 7. | PACS Group, Inc. | $36 | 28.88 | $5.53 B | — | 6.76% | 22.96% | $43.08 / $7.5 | $6.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 7.84 M | 7.93 M | 7.97 M | 8.02 M | 8.07 M |
| Operating Profit | 0.39 M | 1.49 M | 1.06 M | -0.12 M | 1.39 M |
| Net Profit | -3.82 M | 0.36 M | 0.28 M | -1.86 M | 1.05 M |
| EPS in Rs | -0.47 | 0.04 | 0.04 | -0.23 | 0.13 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 31.57 M | 31.99 M | 31.34 M | 30.34 M |
| Operating Profit | 4.84 M | 3.79 M | 3.49 M | 4.46 M |
| Net Profit | -2.43 M | 0.4 M | -9.52 M | 2.77 M |
| EPS in Rs | -0.3 | 0.05 | -1.18 | 0.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 61.73 M | 64.68 M | 61.22 M | 64.89 M |
| Total Liabilities | 80.33 M | 77.89 M | 72.25 M | 66.41 M |
| Equity | -18.61 M | -13.22 M | -11.03 M | -1.52 M |
| Current Assets | 11.76 M | 12.55 M | 9.45 M | 9.61 M |
| Current Liabilities | 19.79 M | 21.6 M | 20.86 M | 19.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 5.48 M | 6.01 M | 8.92 M | 8.57 M |
| Investing CF | -0.98 M | -4.88 M | -8.14 M | -15.28 M |
| Financing CF | -4.75 M | -0.98 M | -2.07 M | 0.15 M |
| Free CF | 5.25 M | 2.41 M | 1.28 M | -8.6 M |
| Capex | -0.23 M | -3.6 M | -7.64 M | -17.17 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 2.05% | 3.32% | — | — |
| Earnings Growth % | 104.22% | -443.57% | — | — |
| Profit Margin % | 1.26% | -30.38% | 9.14% | — |
| Operating Margin % | 11.84% | 11.14% | 14.7% | — |
| Gross Margin % | 75.15% | 73.23% | 71.02% | — |
| EBITDA Margin % | 17.79% | -33.24% | 21.92% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2025-05-21 | $0.15 |
| 2025-02-14 | $0.25 |
| 2024-11-15 | $0.25 |
| 2022-09-01 | $0.9 |
Stock Splits
No stock split history available.